Mateon Therapeutics Inc Stock price OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | 0.00% |
Mar. 25 | Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients | CI |
Nov. 15 | Earnings Flash (OTLC) ONCOTELIC THERAPEUTICS Posts Q3 Revenue $70,000 | MT |
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 17.6M |
---|---|---|---|---|---|
Net income 2021 | -9M | Net income 2022 | 5M | EV / Sales 2021 | - |
Net Debt 2021 | 8.42M | Net Debt 2022 | 11.02M | EV / Sales 2022 | - |
P/E ratio 2021 |
-5.42
x | P/E ratio 2022 |
4.5
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 45.1% |
Managers | Title | Age | Since |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 19-04-21 |
Director of Finance/CFO | 57 | 19-06-30 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 20-01-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven W. King
BRD | Director/Board Member | 59 | 20-05-10 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 71 | 20-05-10 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 19-04-21 |
1st Jan change | Capi. | |
---|---|---|
+2.56% | 108B | |
+10.02% | 104B | |
+7.63% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |
- Stock
- Equities
- Stock Oncotelic Therapeutics, Inc.
- Stock Mateon Therapeutics Inc - OTC Bulletin Board